IPP Bureau
Dr Agarwal's Eye Hospital merges with parent Dr Agarwal's Health Care
By IPP Bureau - August 29, 2025
Merger is expected to streamline operations and provide unified management focus, driving efficiency and strategic alignment
FDA approves Teva Pharmaceuticals' first GLP-1 obesity drug
By IPP Bureau - August 29, 2025
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
Piramal Pharma Solutions supports George Medicines in developing new drug for hypertension
By IPP Bureau - August 29, 2025
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Lilly's oral GLP-1 orforglipron succeeds in Phase 3 trial
By IPP Bureau - August 29, 2025
Triggering global regulatory submissions this year for the treatment of obesity
Moderna receives FDA approval for updated COVID-19 vaccines for LP.8.1 Variant of SARS-CoV-2
By IPP Bureau - August 29, 2025
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
Sai Life Sciences completes Phase II of production block 11 at Bidar
By IPP Bureau - August 29, 2025
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Zydus Therapeutics reports positive phase-3 results in rare liver disease
By IPP Bureau - August 29, 2025
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
AbbVie to acquire Gilgamesh Pharmaceuticals’ bretisilocin for $1.2 billion
By IPP Bureau - August 28, 2025
Lighthouse receives $49.2 million NIA grant to advance phase 2 study of Alzheimer’s disease
By IPP Bureau - August 28, 2025
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
argenx reports positive phase 3 ADAPT SERON results of VYVGART in AChR-Ab seronegative gMG
By IPP Bureau - August 28, 2025
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
FDA expands Repatha indication to adults at risk of major cardiovascular events from uncontrolled LDL-C
By IPP Bureau - August 28, 2025
The FDA also expanded Repatha’s use as monotherapy to include patients with homozygous familial hypercholesterolemia
Samsung India introduces next-gen mobile CT imaging solutions
By IPP Bureau - August 28, 2025
The new lineup includes CereTom Elite, OmniTom Elite, OmniTom Elite PCD, and BodyTom 32/64
Thermo Fisher opens pipette manufacturing site in North Carolina
By IPP Bureau - August 28, 2025
New manufacturing facility in Mebane to produce at least 40 million laboratory pipette tips per week
Gilead’s Yeytuo approved in EU for HIV prevention
By IPP Bureau - August 28, 2025
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
FDA approves Coya Therapeutics’ trial of COYA 302 for ALS
By IPP Bureau - August 28, 2025
As part of its partnership with Dr. Reddy’s Laboratories (DRL), FDA acceptance also triggers a $4.2 million milestone payment to Coya
